Conventional Radiological Profile of Metastatic Bone Disease Based on Its Histopathological Results: A 3-Year Experience
Downloads
Highlights:
1. The incidence of MBD tends to be more frequent in older ages and in female patients.
2. The radiological appearance of a lesion tends to differ depending on its primary tumor.
3. Pathological fracture was present in 55.37% of the cases.
Abstract
Introduction: Metastasis commonly occurs in the bone, termed metastatic bone disease (MBD). Early diagnosis and intervention are important to prolong and increase the quality of life. Although conventional radiology is less sensitive for diagnosing this disease, it remains the most cost and time-efficient screening method. This study aimed to describe the radiological profile of patients diagnosed with MBD based on its histopathological result.
Methods: This was a descriptive retrospective study using medical records and digital radiological data of patients diagnosed with MBD from 2019-2021 in Dr. Soetomo General Academic Hospital, Surabaya. Variables in this study include gender, age, histopathological result, location of metastases, number of lesions, lesion density, and pathological fracture.
Results: 51 patients were diagnosed with MBD during the period of the study and sorted into 121 cases based on metastases location. MBD is more frequent in older female patients, where lesion mostly originates from the breast, thyroid, and lungs, with adenocarcinoma as the most common histology. Vertebrae were the most common location of metastases. Most lesion tends to be multiple and osteolytic. However, certain lesions from different primary tumor had different predilections. Pathological fracture was present in 55.37% of cases.
Conclusion: MBD needs to be suspected in patients with cancer from the breast, thyroid, and lungs as its incidence is higher. More studies about MBD profiles on a larger scale should be conducted to better represent this disease in the general population.
Zajączkowska R, Kocot-Kępska M, Leppert W, et al. Bone Pain in Cancer Patients: Mechanisms and Current Treatment. International Journal of Molecular Sciences; 20. Epub ahead of print 2019. [PubMed]
Wood SL, Brown JE. Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases. Cancers (Basel); 12. Epub ahead of print July 2020. [PubMed]
Ryan C, Stoltzfus KC, Horn S, et al. Epidemiology of Bone Metastases. Bone 2022; 158: 115783. [ScienceDirect]
Jiang W, Rixiati Y, Zhao B, et al. Incidence, Prevalence, and Outcomes of Systemic Malignancy with Bone Metastases. J Orthop Surg (Hong Kong) 2020; 28: 2309499020915989. [PubMed]
Burr DB, Allen MR. Basic and Applied Bone Biology. Elsevier Science, https://books.google.co.id/books?id=JfEqugEACAAJ (2019).
Riihimäki M, Thomsen H, Sundquist K, et al. Clinical Landscape of Cancer Metastases. Cancer Med 2018; 7: 5534–5542. [PubMed]
Akhtar M, Haider A, Rashid S, et al. Paget's ‘Seed and Soil' Theory of Cancer Metastasis: An Idea Whose Time has Come. Adv Anat Pathol 2019; 26: 69–74. [PubMed]
Wu X, Li F, Dang L, et al. RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies. Front Cell Dev Biol 2020; 8: 76. [PubMed]
Quiroz-Munoz M, Izadmehr S, Arumugam D, et al. Mechanisms of Osteoblastic Bone Metastasis in Prostate Cancer: Role of Prostatic Acid Phosphatase. J Endocr Soc 2019; 3: 655–664. [PubMed]
Downie S, Bryden E, Perks F, et al. Diagnosis and Referral of Adults with Suspected Bony Metastases. BMJ 2021; 372: n98. [PubMed]
Oprea-Lager DE, Cysouw MCF, Boellaard R, et al. Bone Metastases are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. Front Oncol 2021; 11: 772530. [PubMed]
Janevska V. Demographic and Morphologic Characteristics of Bone Metastases -11 Years Single Center Experience. 2021; 4: 65–76. [Journal]
Terracina S, Ferraguti G, Petrella C, et al. Characteristic Hallmarks of Aging and the Impact on Carcinogenesis. Curr Cancer Drug Targets 2023; 23: 87–102. [PubMed]
Hong S, Youk T, Lee SJ, et al. Bone Metastasis and Skeletal-Related Events in Patients with Solid Cancer: A Korean Nationwide Health Insurance Database Study. PLoS One 2020; 15: e0234927. [PubMed]
Schmid-Alliana A, Schmid-Antomarchi H, Al-Sahlanee R, et al. Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets. Int J Mol Sci; 19. Epub ahead of print January 2018. [PubMed]
Baliyan A, Punia RS, Kundu R, et al. Histopathological Spectrum of Bone Changes in Skeletal Metastasis. Indian J Med Paediatr Oncol 2019; 40: 476–480. [Journal]
da Silva GT, Bergmann A, Thuler LCS. Incidence and Risk Factors for Bone Metastasis in Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev 2019; 20: 45–51. [PubMed]
Song Q, Shang J, Zhang C, et al. Impact of the Homogeneous and Heterogeneous Risk Factors on the Incidence and Survival Outcome of Bone Metastasis in NSCLC Patients. J Cancer Res Clin Oncol 2019; 145: 737–746. [PubMed]
Zhang J, Wu J. The Potential Roles of Exosomal miR-214 in Bone Metastasis of Lung Adenocarcinoma. Front Oncol 2020; 10: 611054. [PubMed]
Deng Y, Bi R, Zhu Z, et al. A Surveillance, Epidemiology and End Results Database Analysis of the Prognostic Value of Organ-Specific Metastases in Patients with Advanced Prostatic Adenocarcinoma. Oncol Lett 2019; 18: 1057–1070. [PubMed]
Hui M, Balu B, Uppin SG, et al. Bone Metastases: A Compilation of 365 Histologically Verified Cases Spanning over Two Decades from a Single Center. Indian J Pathol Microbiol 2021; 64: 717–724. [PubMed]
Hí¸ilund-Carlsen PF, Hess S, Werner TJ, et al. Cancer Metastasizes to the Bone Marrow and Not to the Bone: Time for a Paradigm Shift! European Journal of Nuclear Medicine and Molecular Imaging 2018; 45: 893–897. [PubMed]
Onken JS, Fekonja LS, Wehowsky R, et al. Metastatic Dissemination Patterns of Different Primary Tumors to the Spine and Other Bones. Clin Exp Metastasis 2019; 36: 493–498. [PubMed]
Shen F, Huang J, Yang K, et al. A Comprehensive Review of Interventional Clinical Trials in Patients with Bone Metastases. Onco Targets Ther 2023; 16: 485–495. [PubMed]
Edwards CM, Johnson RW. From Good to Bad: The Opposing Effects of PTHrP on Tumor Growth, Dormancy, and Metastasis Throughout Cancer Progression. Front Oncol 2021; 11: 644303. [PubMed]
Wong SK, Mohamad N-V, Giaze TR, et al. Prostate Cancer and Bone Metastases: The Underlying Mechanisms. Int J Mol Sci; 20. Epub ahead of print May 2019. [PubMed]
Tyson J, Bundy K, Roach C, et al. Mechanisms of the Osteogenic Switch of Smooth Muscle Cells in Vascular Calcification: WNT Signaling, BMPs, Mechanotransduction, and EndMT. Bioeng (Basel, Switzerland); 7. Epub ahead of print August 2020. [PubMed]
Lin S-R, Mokgautsi N, Liu Y-N. Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis. Molecules; 25. Epub ahead of print May 2020. [PubMed]
Wang M, Xia F, Wei Y, et al. Molecular Mechanisms and Clinical Management of Cancer Bone Metastasis. Bone Res 2020; 8: 30. [Journal]
Zhang R, Li J, Assaker G, et al. Parathyroid Hormone-Related Protein (PTHrP): An Emerging Target in Cancer Progression and Metastasis. Adv Exp Med Biol 2019; 1164: 161–178. [PubMed]
Rossi M, Battafarano G, D'Agostini M, et al. The Role of Extracellular Vesicles in Bone Metastasis. Int J Mol Sci; 19. Epub ahead of print April 2018. [PubMed]
Hiraga T. Bone Metastasis: Interaction between Cancer Cells and Bone Microenvironment. J Oral Biosci 2019; 61: 95–98. [PubMed]
Jairam V, Lee V, Yu JB, et al. Nationwide Patterns of Pathologic Fractures among Patients Hospitalized with Bone Metastases. Am J Clin Oncol 2020; 43: 720–726. [PubMed]
Garry P, Edward M, Setiawati R, et al. Clinical Features in Metastatic Bone Disease with and without Pathological Fractures: A Comparative Study. Heal Notions; 3. Epub ahead of print 25 October 2019. [Journal]
Copyright (c) 2023 Braven Armando, Rosy Setiawati, Mouli Edward, Sjahjenny Mustokoweni
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The formal legal aspect of journal publication accessibility refers to Creative Commons Atribution-Share Alike 4.0 (CC BY-SA).